R788 Fostamatinib Disodium is a small molecule inhibitor of the spleen tyrosine kinase (SYK). It is currently being studied as a potential treatment for various autoimmune diseases, including rheumatoid arthritis and immune thrombocytopenia. R788 Fostamatinib Disodium was first developed by Rigel Pharmaceuticals, Inc. and has undergone several clinical trials.
Chemical Name
The chemical name of R788 Fostamatinib Disodium is disodium 6-(2,5-dimethoxyphenyl)-2-{[(2,2-dimethyl-7-oxo-3,4-dihydrobenzo[b][1,4]oxazepin-9-yl)amino]methyl}-1,3,5-triazine-4,7-dione.
Molecular Formula
The molecular formula of R788 Fostamatinib Disodium is C23H24N6Na2O6S.
Formula Weight
The formula weight of R788 Fostamatinib Disodium is 602.56 g/mol.
CAS No.
The CAS number of R788 Fostamatinib Disodium is 1025687-58-4.
Top Ten Keywords from Google and Synonyms
Synonyms: Fostamatinib Disodium, R 788, R-788, R788, N-(6-(2,5-Dimethoxyphenyl)-2-((2,2-dimethyl-7-oxo-3,4-dihydrobenzo[b][1,4]oxazepin-9-yl)amino)-4,5-dihydro-1,3,5-triazin-4-yl)acetamide disodium salt hydrate
Health Benefits of R788 Fostamatinib Disodium
R788 Fostamatinib Disodium has shown promising results in treating various autoimmune diseases, particularly rheumatoid arthritis and immune thrombocytopenia. By inhibiting SYK, a protein that plays a key role in B-cell receptor signaling, R788 Fostamatinib Disodium works to suppress the immune system and reduce inflammation.
Potential Effects
Clinical studies have shown that R788 Fostamatinib Disodium can effectively treat rheumatoid arthritis and immune thrombocytopenia. In one phase II study, researchers found that R788 Fostamatinib Disodium was well-tolerated and showed signs of efficacy in patients with rheumatoid arthritis who were not responding to other treatments.
Product Mechanism
R788 Fostamatinib Disodium works by specifically targeting SYK, a protein that is involved in B-cell receptor signaling and plays a critical role in the activation of immune cells. By inhibiting SYK, R788 Fostamatinib Disodium suppresses the immune response and reduces inflammation, thereby alleviating symptoms of autoimmune diseases such as rheumatoid arthritis and immune thrombocytopenia.
Safety
R788 Fostamatinib Disodium has generally been well-tolerated in clinical trials. However, like all medications, it can cause side effects. Common side effects include diarrhea, nausea, vomiting, and headache. More severe side effects may occur in some patients, such as bleeding or liver damage. Patients should be closely monitored for any adverse reactions while taking R788 Fostamatinib Disodium.
Side Effects
The most common side effects of R788 Fostamatinib Disodium include:
More severe side effects may occur in some patients, such as:
Dosing Information
The dosing of R788 Fostamatinib Disodium depends on the type of autoimmune disease being treated and other individual factors. It is typically administered orally in tablet form, either alone or in combination with other immunomodulatory drugs. The recommended dose varies depending on the clinical trial or physician's discretion.
Conclusion
In conclusion, R788 Fostamatinib Disodium is a promising drug candidate for the treatment of autoimmune diseases, particularly rheumatoid arthritis and immune thrombocytopenia. As an inhibitor of SYK, it shows potential in suppressing the immune response and reducing inflammation, thereby alleviating symptoms of these debilitating conditions. While further clinical trials are needed to determine its efficacy and safety, R788 Fostamatinib Disodium represents an important step
